XML 45 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity - Equity (Tables)
12 Months Ended
Dec. 31, 2017
Equity [Abstract]  
Share-based Compensation, Stock Options, Activity [Table Text Block]
The following tables summarize stock options, SARs, and non-vested restricted stock activity for the years ended December 31, 2017, 2016, and 2015:

Table 9.1

  
For the Year Ended December 31,
 
2017
 
2016
 
2015
 
Stock
Options
and
SARs
 
Weighted-
Average
Exercise
Price
 
Stock
Options
and
SARs
 
Weighted-
Average
Exercise
Price
 
Stock
Options
and
SARs
 
Weighted-
Average
Exercise
Price
Outstanding, beginning of year
367,535

 
$
30.18

 
747,573

 
$
26.68

 
718,143

 
$
25.12

Granted
24,657

 
60.84

 
51,975

 
35.75

 
119,110

 
32.25

Exercised
(111,278
)
 
31.47

 
(431,346
)
 
24.77

 
(86,680
)
 
21.32

Canceled
(117,642
)
 
31.55

 
(667
)
 
35.60

 
(3,000
)
 
30.05

Outstanding, end of year
163,272

 
32.95

 
367,535

 
30.18

 
747,573

 
26.68

Exercisable at end of year
93,085

 
28.57

 
208,274

 
27.41

 
543,698

 
24.34

 
 
 
 
 
 
 
 
 
 
 
 
 
For the Year Ended December 31,
 
2017
 
2016
 
2015
 
Non-vested
Restricted
Stock
 
Weighted-
Average
Grant Date
Fair Value
 
Non-vested
Restricted
Stock
 
Weighted-
Average
Grant Date
Fair Value
 
Non-vested
Restricted
Stock
 
Weighted-
Average
Grant Date
Fair Value
Outstanding, beginning of year
138,497

 
$
34.63

 
132,651

 
$
32.12

 
103,772

 
$
31.24

Granted
45,828

 
59.79

 
76,617

 
36.33

 
76,616

 
32.14

Canceled
(28,815
)
 
42.15

 
(1,360
)
 
35.75

 

 

Vested and issued
(60,495
)
 
34.77

 
(69,411
)
 
31.69

 
(47,737
)
 
30.25

Outstanding, end of year
95,015

 
44.39

 
138,497

 
34.63

 
132,651

 
32.12

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]
The following tables summarize information regarding SARs and non-vested restricted stock outstanding as of December 31, 2017:

Table 9.2

 
 
Outstanding
 
Exercisable
 
Vested or Expected to Vest
Range of
Exercise Prices
 
SARs
 
Weighted-
Average Remaining Contractual Life
 
SARs
 
Weighted-
Average Remaining Contractual Life
 
SARs
 
Weighted-
Average Remaining Contractual Life
$5.00 - $14.99
 
11,000

 
2.5 years
 
11,000

 
2.5 years
 
11,000

 
2.5 years
15.00 - 24.99
 
14,000

 
4.0 years
 
14,000

 
4.0 years
 
14,000

 
4.0 years
25.00 - 34.99
 
82,689

 
6.8 years
 
46,163

 
6.5 years
 
82,689

 
6.8 years
35.00 - 44.99
 
41,588

 
7.5 years
 
21,922

 
6.9 years
 
41,588

 
7.5 years
45.00 - 54.99
 

 
0.0 years
 

 
0.0 years
 

 
0.0 years
55.00 - 64.99
 
13,995

 
9.3 years
 

 
0.0 years
 
13,995

 
9.3 years
 
 
163,272

 
 
 
93,085

 
 
 
163,272

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outstanding
 
Expected to Vest
 
 

 
  
  Weighted-
Average
Grant-Date
Fair Value
 
 Non-vested Restricted Stock
 
Weighted-Average Remaining Contractual
Life
 
 Non-vested Restricted Stock
 
Weighted-Average Remaining Contractual
Life
 
 

 
  
$25.00 - $34.99
 
6,778

 
0.1 years
 
6,778

 
0.1 years
 
 
 
 
35.00 - 44.99
 
50,882

 
1.5 years
 
50,882

 
1.5 years
 
 
 
 
45.00 - 54.99
 

 
0.0 years
 

 
0.0 years
 
 
 
 
55.00 - 64.99
 
37,355

 
2.3 years
 
37,355

 
2.3 years
 
 
 
 
 
 
95,015

 
 
 
95,015

 
 
 
 
 
 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
The weighted average exercise price of the 163,272 SARs vested or expected to vest as of December 31, 2017 was $32.95.

As of December 31, 2017 and 2016, the intrinsic value of options, SARs, and non-vested restricted stock outstanding, exercisable, and vested or expected to vest was $14.8 million and $17.4 million, respectively.  During 2017, 2016, and 2015, the total intrinsic value of options and SARs exercised was $3.8 million, $7.6 million, and $0.9 million, respectively.  As of December 31, 2017, there was $2.3 million of total unrecognized compensation cost related to non-vested SARs and restricted stock awards.  This cost is expected to be recognized over a weighted-average period of 1.7 years.

The weighted-average grant date fair values of options, SARs, and restricted stock awards granted in 2017, 2016, and 2015 were $44.93, $25.11, and $17.97 per share, respectively.  Under the fair value-based method of accounting for stock-based compensation cost, Farmer Mac recognized compensation expense of $2.7 million, $3.3 million, and $3.3 million during 2017, 2016, and 2015, respectively.  

The fair values of stock options and SARs were estimated using the Black-Scholes option pricing model based on the following assumptions:

Table 9.3

 
For the Year Ended December 31,
 
2017
 
2016
 
2015
Risk-free interest rate
2.3%
 
1.5%
 
1.2%
Expected years until exercise
6 years
 
5 years
 
4 years
Expected stock volatility
34.8%
 
34.7%
 
38.0%
Dividend yield
2.4%
 
2.9%
 
2.0%

The risk-free interest rates used in the model were based on the U.S. Treasury yield curve in effect at the grant date.  Farmer Mac used historical data to estimate the timing of option exercises and stock option cancellation rates used in the model.  Expected volatilities were based on historical volatility of Farmer Mac's Class C non-voting common stock.  The dividend yields were based on the expected dividends as a percentage of the value of Farmer Mac's Class C non-voting common stock on the grant date.

Because restricted stock awards will be issued upon vesting regardless of the stock price, expected stock volatility is not considered in determining grant date fair value.  Restricted stock awards also accrue dividends which are paid at vesting.  The weighted-average grant date fair value of the restricted stock awarded in 2017, 2016, and 2015 was $59.79, $36.33, and $32.14 per share, respectively, which is based on the closing price of the stock on the date granted.